STORY: Novo Nordisk said Wednesday it would cut costs as it takes on growing competition.The Danish firm faces a growing ...

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

Shares of Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, fell in pre-market trading and on the ...

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop ...

Super Micro, AMD, and Snap stocks tumbled after quarterly earnings reports. Arista and Disney stocks were rising.

President Trump’s latest tariff threat has targeted a sector that’s already hobbled.

No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.

The $210 bln Ozempic maker spends less than rivals on developing new drugs. That’s a problem as upstarts challenge its blockbuster obesity medication. Loading up the research budget will eat into the ...

Danish pharmaceutical firm Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, announced Wednesday a 32 percent increase in net profit for the second ...